Mirna Therapeutics halts phase 1 clinical study of MRX34
Wednesday, September 21, 2016
Mirna Therapeutics Inc Will discuss with advisors, as well as fda regarding possible future development of MRX34. Company voluntarily halted enrollment and dosing in clinical study following multiple immune-related severe adverse events.
Will not be initiating a translational medicine study of MRX34 in melanoma patients, planned to begin later this year.
Source : reuters.com
